GlassScriptPhysician profile
Mohammed Syed
NPI 1972031664
$5,359.60
in general payments reported to CMS, 2019-2025
38 companies · $1,156 in 2025
The $1,156 reported for 2025 was more than what 87% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $80.85 · 2022: $871 · 2023: $1,749 · 2024: $1,502 · 2025: $1,156.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,408.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,407.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $1,613.31 | 2022-2024 | Injectafer |
| Pfizer INC. | $493.64 | 2022-2025 | |
| Abbvie INC. | $356.28 | 2023-2025 | Ubrelvy |
| Lilly USA, LLC | $294.16 | 2023-2025 | Mounjaro, Zepbound |
| Novo Nordisk INC | $273.60 | 2022-2025 | Wegovy, Ozempic, Rybelsus |
| Acadia Pharmaceuticals INC | $264.20 | 2022-2024 | Nuplazid |
| Astrazeneca Pharmaceuticals LP | $208.92 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Esperion Therapeutics, INC. | $179.11 | 2024 | Nexletol, Nexlizet |
| Amgen INC. | $162.94 | 2022-2025 | Evenity, Prolia, Krystexxa |
| Glaxosmithkline, LLC. | $155.50 | 2022-2025 | Shingrix, Arexvy |
| Alexion Pharmaceuticals, INC. | $142.76 | 2025 | Koselugo |
| Otsuka America Pharmaceutical, INC. | $131.46 | 2023-2025 | Rexulti |
| Merck Sharp & Dohme LLC | $127.06 | 2022-2024 | Verquvo, Belsomra, Steglatro |
| Dexcom, INC. | $107.58 | 2024-2025 | Dexcom G6 Transmitter |
| La Jolla Pharmaceutical Company | $92.91 | 2023 | Xerava |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $76.87 | 2023-2024 | Jardiance |
| Lundbeck LLC | $70.71 | 2023-2025 | Rexulti, Vyepti |
| Pylant Medical | $57.46 | 2024 | |
| Astellas Pharma US INC | $55.55 | 2023-2025 | Veozah, Myrbetriq |
| Takeda Pharmaceuticals U.S.A., INC. | $50.44 | 2021 | |
| Axsome Therapeutics, INC. | $43.53 | 2023 | Auvelity |
| Abiomed | $41.86 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $40.89 | 2025 | Eliquis, Camzyos |
| Exact Sciences Corporation | $39.56 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Shield Therapeutics INC | $37.71 | 2024-2025 | |
| Idorsia Pharmaceuticals US INC | $34.70 | 2022-2023 | Quviviq |
| Vertex Pharmaceuticals Incorporated | $24.03 | 2025 | |
| Argon Medical Devices, INC. | $23.11 | 2023 | Biopince, Cleaner |
| Eisai INC. | $22.22 | 2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $17.99 | 2022 | |
| Abbott Laboratories | $17.98 | 2023 | Freestyle Libre 3 |
| Bayer Healthcare Pharmaceuticals INC. | $16.67 | 2023 | |
| Mallinckrodt Hospital Products INC. | $15.87 | 2023 | Terlivaz |
| Inogen, INC. | $15.15 | 2023 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Novartis Pharmaceuticals Corporation | $14.09 | 2023 | |
| Xeris Pharmaceuticals, INC. | $13.83 | 2025 | Gvoke Hypopen |
| Evoke Pharma, INC. | $13.80 | 2024 | |
| Sanofi-Aventis U.S. LLC | $12.15 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammed Syed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.